Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.

Published in: American journal of hematology (2024)

Allogeneic stem cell transplant continues to be the curative therapy for most aggressive subtypes of PTCL. The use of checkpoint inhibitors in the treatment of PTCL is still controversial, with best results seen in cases of extranodal natural killer cell/T-cell lymphoma. Bispecific antibody-based treatments and chimeric antigen receptor cell-based therapies are in clinical trials.

Keyphrases

stem cells
clinical trial
single cell
cell therapy
stem cell transplantation
bone marrow
dna damage
cell cycle
open label